-
1.
公开(公告)号:US20190233466A1
公开(公告)日:2019-08-01
申请号:US16277861
申请日:2019-02-15
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号:US10208082B2
公开(公告)日:2019-02-19
申请号:US15510208
申请日:2015-09-09
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号:US09212170B2
公开(公告)日:2015-12-15
申请号:US14495052
申请日:2014-09-24
发明人: Atsunobu Sakamoto , Naoki Tanaka , Takeshi Fukuda
IPC分类号: C07D403/04 , C07D401/14 , C07D401/04 , A61K31/4439 , A61K31/415 , C07C59/01 , A61K9/00 , A61K47/10 , A61K9/20 , A61K9/48
CPC分类号: C07D403/04 , A61K9/0019 , A61K9/2018 , A61K9/4866 , A61K31/415 , A61K31/4439 , A61K47/10 , C07C59/01 , C07D401/04 , C07D401/14
摘要: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides, for example, a compound represented by the formula (1) wherein R1: -Q1, -Q1-X-Q2, or -Q1-X-Q2-Y-Q3: a monocyclic or bicyclic aromatic heterocyclic group; Q2, Q3: an aromatic hydrocarbon ring group or a monocyclic aromatic heterocyclic group; X: —CONH—, —CONHCH2—, —CH2OCH2—, —NHCH2CH2—, or the like; Y: a single bond, —O—, —(CH2)n—, or —O—(CH2)n—; m, n: an integer from 1 to 3; R2: H or an alkyl group; and R3: H, an alkoxycarbonyl group, a carboxy group, an aromatic hydrocarbon ring group, or a monocyclic aromatic heterocyclic group.
摘要翻译: 本发明提供了促进促红细胞生成素生成的化合物。 本发明提供例如由式(1)表示的化合物,其中R1:-Q1,-Q1-X-Q2或-Q1-X-Q2-Y-Q3:单环或双环芳族杂环基; Q2,Q3:芳香族烃环基或单环式芳香族杂环基; X:-CONH-,-CONHCH 2 - , - CH 2 OCH 2 - , - NHCH 2 CH 2 - 等; Y:单键,-O - , - (CH 2)n - 或-O-(CH 2)n - m,n:1〜3的整数; R2:H或烷基; 和R 3:H,烷氧基羰基,羧基,芳族烃环基或单环芳族杂环基。
-
公开(公告)号:US10808006B2
公开(公告)日:2020-10-20
申请号:US16277861
申请日:2019-02-15
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
5.
公开(公告)号:US20170260228A1
公开(公告)日:2017-09-14
申请号:US15510208
申请日:2015-09-09
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
CPC分类号: C07J71/001 , A61K9/0048 , A61K9/1647 , A61K9/204 , A61K31/58 , A61P27/02 , C07J63/008 , Y02A50/473
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
-
-
-